11/13
01:27 pm
lptx
Leap Therapeutics (NASDAQ:LPTX) is now covered by analysts at
Weiss Ratings. They set a "sell (e+)" rating on the stock.
Neutral
Report
Leap Therapeutics (NASDAQ:LPTX) is now covered by analysts at
Weiss Ratings. They set a "sell (e+)" rating on the stock.
11/13
09:18 am
lptx
Solana in the Shade: Crypto Daybook Americas [Yahoo! Finance]
Neutral
Report
Solana in the Shade: Crypto Daybook Americas [Yahoo! Finance]
11/12
10:48 pm
lptx
Will Winklevoss Twins Successfully Takeover ZCash? [Yahoo! Finance]
Neutral
Report
Will Winklevoss Twins Successfully Takeover ZCash? [Yahoo! Finance]
11/12
06:11 pm
lptx
Winklevoss-backed stock halted multiple times after wild 550% rally [Yahoo! Finance]
High
Report
Winklevoss-backed stock halted multiple times after wild 550% rally [Yahoo! Finance]
11/12
10:41 am
lptx
BC-Most Active Stocks [Yahoo! Finance]
High
Report
BC-Most Active Stocks [Yahoo! Finance]
11/12
09:27 am
lptx
Cypherpunk Technologies GAAP EPS of -$0.08 [Seeking Alpha]
High
Report
Cypherpunk Technologies GAAP EPS of -$0.08 [Seeking Alpha]
11/12
08:00 am
lptx
Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results
High
Report
Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results
11/12
08:00 am
lptx
Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results
High
Report
Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results
11/12
08:00 am
lptx
Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results
High
Report
Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results
11/12
07:00 am
lptx
Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy
High
Report
Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy
11/12
07:00 am
lptx
Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy
High
Report
Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy
11/12
07:00 am
lptx
Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy
High
Report
Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy
10/20
07:00 am
lptx
Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025
Medium
Report
Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025
10/9
07:00 am
lptx
Leap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy
Medium
Report
Leap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy
10/6
09:08 am
lptx
Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy [Yahoo! Finance]
High
Report
Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy [Yahoo! Finance]
10/6
09:00 am
lptx
Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy
High
Report
Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy
9/25
07:35 am
lptx
Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025 [Yahoo! Finance]
High
Report
Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025 [Yahoo! Finance]
9/25
07:00 am
lptx
Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025
High
Report
Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025